Tirzepatide: difference between revisions
Diff·revision 13 → 14·06:29, 6 Dec 2024
Difference between revision 13 and revision 14 of Tirzepatide. 3 lines changed; the page grew by 225 bytes.
| Revision 13 — 21:47, 16 Nov 2024 OralSemaOswin (talk) fix the anchor on an internal link 5,120 bytes +131 | Revision 14 — 06:29, 6 Dec 2024 OrforglipronOona (talk) de-duplicate a repeated sentence 5,345 bytes +225 | ||
|---|---|---|---|
| 43 | The [[SURPASS trial programme|SURPASS]] programme covers the glycaemic indication and the [[SURMOUNT trial programme|SURMOUNT]] programme the obesity indication. SURPASS-2 is one of the few head-to-head trials in this field, comparing tirzepatide directly with semaglutide 1 mg — not the 2.4 mg obesity dose, a distinction routinely lost when the trial is cited.{{r|frias2021}} | 43 | The [[SURPASS trial programme|SURPASS]] programme covers the glycaemic indication and the [[SURMOUNT trial programme|SURMOUNT]] programme the obesity indication. SURPASS-2 is one of the few head-to-head trials in this field, comparing tirzepatide directly with semaglutide 1 mg — not the 2.4 mg obesity dose, a distinction routinely lost when the trial is cited.{{r|frias2021}} |
| 44 | 44 | ||
| + | 45 | Discontinuation for adverse events across the programme ran at roughly 4–7% on active treatment, comparable with other agents in the field despite the larger effect size.{{r|jastreboff2022}} | |
| + | 46 | ||
| 45 | == References == | 47 | == References == |
| 46 | {{reflist}} | 48 | {{reflist}} |
| ⋮ | ⋮ | ||
| 54 | * [[Retatrutide]] | 56 | * [[Retatrutide]] |
| 55 | * [[Glucose-dependent insulinotropic polypeptide]] | 57 | * [[Glucose-dependent insulinotropic polypeptide]] |
| + | 58 | * [[SURMOUNT trial programme]] | |
| 56 | 59 | ||
| 57 | {{DEFAULTSORT:Tirzepatide}} | 60 | {{DEFAULTSORT:Tirzepatide}} |